A singular commitment to cure Duchenne muscular dystrophy
Solid is a life science company singularly focused on developing meaningful therapies for Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, bringing together those with expertise in science, technology, disease management and care. Disease-focused and founded by those directly impacted by Duchenne, our mandate is simple yet comprehensive – attack all facets of the disease and improve the daily lives of patients living with this devastating disease.
Guiding Principles
There is no cure for Duchenne, and there is only one treatment on the market that is approved for a small subset of patients. Solid is purpose-built to identify and develop the most promising approaches to address the disease at all stages.
Singular Focus
We are singularly focused on developing transformative treatments to improve the lives of Duchenne muscular dystrophy patients
Patient Centric
We start with Duchenne patients and their unmet needs.
Collaboration
We are working collectively with all stakeholders — industry, academia, government and community — to advance our gene therapy candidate, SGT-001, to better understand its potential to benefit patients with this devastating disease.
Center of Excellence
We are a catalyst bringing together the best knowledge to address all aspects of the disease.